Janssen Research & Development, LLC Voluntarily Suspends Dosing in Phase 2 Clinical Trials of Experimental Treatment for Mood Disorders

Precautionary Measure Follows Safety Issue with Different Drug in Class

At Janssen, the safety and well-being of patients who participate in our clinical trials are most important. 

As a precaution, Janssen is voluntarily suspending dosing in two Phase 2 clinical studies of an experimental medicine -- a FAAH inhibitor -- following reports in France on Friday, January 15, 2016 of serious adverse events in another company's Phase 1 safety study with an experimental drug in this class.

Janssen has not received any reports of serious adverse events in our Phase 2 studies with our FAAH inhibitor in patients with social anxiety disorder and in major depressive disorder with anxious distress, or in earlier, Phase 1 safety studies of the drug.

We have informed health authorities, research sites, and study investigators about the change in status with these studies and instructed investigators to inform study patients as soon as possible.  

We have asked clinical trial investigators to instruct study patients to speak to their treating physicians about approved, available medications for their study-related medical conditions.

We will reevaluate our decision to suspend dosing in these clinical trials when we have additional information.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.